Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Vaccines

Free Subscription Articles published in Lancet Retrieve available abstracts of 57 articles: HTML format

Single Articles

May 2025
1. ATERE AO, Mustapha FB, Mustapha MJ
   Logistics of the malaria vaccine roll-out in Nigeria.
   Lancet. 2025;405:1815.
   PubMed    
   
   
   April 2025
2. MARQUES ETA, Burke DS
   Safety and immunogenicity of a virus-like particle Chikungunya virus vaccine.
   Lancet. 2025;405:1314-1315.
   PubMed    
   
   
   
3. NDEMBI N, Karuna S, Cowden J, Cagigi A, et al
   Accelerating vaccine development in Africa: lessons from HIV research.
   Lancet. 2025 Apr 10:S0140-6736(25)00564-1. doi: 10.1016/S0140-6736(25)00564.
   PubMed    
   
   
   March 2025
4. RICHARDSON JS, Anderson DM, Mendy J, Tindale LC, et al
   Chikungunya virus virus-like particle vaccine safety and immunogenicity in adolescents and adults in the USA: a phase 3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2025 Mar 27:S0140-6736(25)00345-9. doi: 10.1016/S0140-6736(25)00345.
   PubMed     Abstract available
   
   
   
5. TINDALE LC, Richardson JS, Anderson DM, Mendy J, et al
   Chikungunya virus virus-like particle vaccine safety and immunogenicity in adults older than 65 years: a phase 3, randomised, double-blind, placebo-controlled trial.
   Lancet. 2025 Mar 27:S0140-6736(25)00372-1. doi: 10.1016/S0140-6736(25)00372.
   PubMed     Abstract available
   
   
   
6. MENSAH AA, Whitaker H, Andrews NJ, Watson CH, et al
   Early impact of RSV vaccination in older adults in England.
   Lancet. 2025 Mar 24:S0140-6736(25)00346-0. doi: 10.1016/S0140-6736(25)00346.
   PubMed    
   
   
   
7. DIALLO F, Haidara FC, Tapia MD, Dominguez Islas CP, et al
   Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine targeting serogroups A, C, W, Y, and X when co-administered with routine childhood vaccines at ages 9 months and 15 months in Mali: a single-centre, double-blind, randomised, c
   Lancet. 2025 Mar 11:S0140-6736(25)00046-7. doi: 10.1016/S0140-6736(25)00046.
   PubMed     Abstract available
   
   
   
8. ALVES L
   Brazil hopes for new vaccine to combat dengue.
   Lancet. 2025;405:770.
   PubMed    
   
   
   February 2025
9. PRASAD A
   Sarah Blagden: designing vaccines for cancer prevention.
   Lancet. 2025;405:613.
   PubMed    
   
   
   
10. NEUPANE D, Jaiswal LS, Koirala S
    Nepal set to launch historic HPV vaccination programme.
    Lancet. 2025;405:375.
    PubMed    
    
    
    January 2025
11. MUMFORD L, Hogg R, Taylor A, Lanyon P, et al
    Impact of SARS-CoV-2 spike antibody positivity on infection and hospitalisation rates in immunosuppressed populations during the omicron period: the MELODY study.
    Lancet. 2025;405:314-328.
    PubMed     Abstract available
    
    
    
12. DATOO MS, Hill AVS, Beaumont E, Bradley J, et al
    The R21/Matrix-M malaria vaccine: questions remain - Author's reply.
    Lancet. 2025;405:299-301.
    PubMed    
    
    
    
13. AABY P, Bjorkman A, Schapira A, Benn CS, et al
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    PubMed    
    
    
    
14. OBARO S, Mokuolu O, Michelow IC
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:299.
    PubMed    
    
    
    
15. LI Y, Liu G
    The R21/Matrix-M malaria vaccine: questions remain.
    Lancet. 2025;405:298-299.
    PubMed    
    
    
    
16. IMPOUMA B, Adidja A, Mboussou F, Cabore J, et al
    Malaria vaccine introduction in Africa: progress and challenges.
    Lancet. 2025 Jan 21:S0140-6736(24)02841-1. doi: 10.1016/S0140-6736(24)02841.
    PubMed    
    
    
    
17. DZAU V, Hatchett R, Bishen S, Kaseya J, et al
    The time for regionalised vaccine manufacturing has arrived.
    Lancet. 2025 Jan 14:S0140-6736(25)00050-9. doi: 10.1016/S0140-6736(25)00050.
    PubMed    
    
    
    December 2024
18. TONY YANG Y
    The perils of RFK Junior's anti-vaccine leadership for public health.
    Lancet. 2024 Dec 18:S0140-6736(24)02603-5. doi: 10.1016/S0140-6736(24)02603.
    PubMed    
    
    
    November 2024
19. INO H, Takimoto Y, Nakazawa E
    Misinformation targeting replicon vaccine recipients: an urgent public health ethical issue.
    Lancet. 2024;404:1922-1923.
    PubMed    
    
    
    October 2024
20. PAYNE AB, Watts JA, Mitchell PK, Dascomb K, et al
    Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis.
    Lancet. 2024;404:1547-1559.
    PubMed     Abstract available
    
    
    
21. BRANDA F, Oh J, Acharya KP, Yon DK, et al
    Human vaccination for highly pathogenic avian influenza.
    Lancet. 2024;404:1518-1519.
    PubMed    
    
    
    
22. BRANCHE AR
    Real-world effectiveness studies of the benefit of RSV vaccines.
    Lancet. 2024;404:1498-1500.
    PubMed    
    
    
    
23. ADEPOJU P
    Rwandan Marburg outbreak sparks vaccine efforts.
    Lancet. 2024;404:1389.
    PubMed    
    
    
    
24. QADRI F, Khanam F, Zhang Y, Biswas PK, et al
    5-year vaccine protection following a single dose of Vi-tetanus toxoid conjugate vaccine in Bangladeshi children (TyVOID): a cluster randomised trial.
    Lancet. 2024;404:1419-1429.
    PubMed     Abstract available
    
    
    
25. AL-MAMUN F, Mamun MA, Roy N
    Long-term efficacy and public health implications of the Vi-tetanus toxoid conjugate vaccine in Bangladeshi children.
    Lancet. 2024;404:1378-1379.
    PubMed    
    
    
    September 2024
26. PHUYAL S, Acharya KP, Yon DK
    Antibody titres after vaccination: a missing key to rabies control.
    Lancet. 2024;404:1192-1193.
    PubMed    
    
    
    
27. SALEEM SM, Jan SS
    Operationalising the One Health approach for rabies elimination.
    Lancet. 2024;404:1191-1192.
    PubMed    
    
    
    
28. ADEPOJU P
    Vaccination under way as mpox cases continue to rise.
    Lancet. 2024;404:1184.
    PubMed    
    
    
    
29. MAZUR NI, Caballero MT, Nunes MC
    Severe respiratory syncytial virus infection in children: burden, management, and emerging therapies.
    Lancet. 2024;404:1143-1156.
    PubMed     Abstract available
    
    
    
30. WALDMAN R, Steinglass R, Nieburg P
    An urgent case for measles vaccination in Gaza.
    Lancet. 2024 Sep 20:S0140-6736(24)02076-2. doi: 10.1016/S0140-6736(24)02076.
    PubMed    
    
    
    
31. PECENKA C, Sparrow E, Feikin DR, Srikantiah P, et al
    Respiratory syncytial virus vaccination and immunoprophylaxis: realising the potential for protection of young children.
    Lancet. 2024 Sep 6:S0140-6736(24)01699-4. doi: 10.1016/S0140-6736(24)01699.
    PubMed     Abstract available
    
    
    
32. NTUMBA HCK, Mandja BM
    Mpox in eastern Democratic Republic of the Congo: challenges and prospects for vaccination.
    Lancet. 2024 Sep 2:S0140-6736(24)01806-3. doi: 10.1016/S0140-6736(24)01806.
    PubMed    
    
    
    August 2024
33. ZHONG L, Zhao Q, Zeng MS, Zhang X, et al
    Prophylactic vaccines against Epstein-Barr virus.
    Lancet. 2024;404:845.
    PubMed    
    
    
    
34. NEUZIL KM, Patel PD, Ndeketa L, Laurens MB, et al
    Efficacy of typhoid conjugate vaccine in Malawian children - Authors' reply.
    Lancet. 2024;404:748.
    PubMed    
    
    
    
35. OBARO S
    Efficacy of typhoid conjugate vaccine in Malawian children.
    Lancet. 2024;404:747-748.
    PubMed    
    
    
    
36. SCHIFFMAN M, de Sanjose S
    The rational design of cervical cancer prevention strategies.
    Lancet. 2024;404:406-407.
    PubMed    
    
    
    July 2024
37. ADEPOJU P
    African mpox surges show lack of vaccine access.
    Lancet. 2024;404:18.
    PubMed    
    
    
    June 2024
38. LI P, Meng Z, Zhou Z, Zhong Z, et al
    Therapeutic vaccines for Epstein-Barr virus: a way forward.
    Lancet. 2024;403:2779-2780.
    PubMed    
    
    
    
39. HO A, Galgut O, Faustini S, Peters N, et al
    Implications of suboptimal measles immunity in UK health-care workers.
    Lancet. 2024 Jun 26:S0140-6736(24)01011-0. doi: 10.1016/S0140-6736(24)01011.
    PubMed    
    
    
    
40. SAMARASEKERA U
    African vaccine manufacturing scheme to boost production.
    Lancet. 2024;403:2579-2580.
    PubMed    
    
    
    
41. ASHINZE P, Mafua N, Obafemi E
    Nigeria rolls out novel meningitis vaccine.
    Lancet. 2024;403:2373.
    PubMed    
    
    
    May 2024
42. LAXMINARAYAN R, Impalli I, Rangarajan R, Cohn J, et al
    Expanding antibiotic, vaccine, and diagnostics development and access to tackle antimicrobial resistance.
    Lancet. 2024 May 20:S0140-6736(24)00878-X. doi: 10.1016/S0140-6736(24)00878.
    PubMed     Abstract available
    
    
    
43. ADAMU AA, Ndwandwe D, Jalo RI, Muhammad ID, et al
    Cofinancing immunisation through national health insurance.
    Lancet. 2024;403:1983-1984.
    PubMed    
    
    
    
44. SHATTOCK AJ, Johnson HC, Sim SY, Carter A, et al
    Contribution of vaccination to improved survival and health: modelling 50 years of the Expanded Programme on Immunization.
    Lancet. 2024 May 2:S0140-6736(24)00850-X. doi: 10.1016/S0140-6736(24)00850.
    PubMed     Abstract available
    
    
    April 2024
45. COULBORN RM, Danet C, Alsalhani A
    Measles and rubella vaccine microneedle patch: new hope to reach the unreached children.
    Lancet. 2024 Apr 29:S0140-6736(24)00749-9. doi: 10.1016/S0140-6736(24)00749.
    PubMed    
    
    
    
46. ADIGWEME I, Yisa M, Ooko M, Akpalu E, et al
    A measles and rubella vaccine microneedle patch in The Gambia: a phase 1/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial.
    Lancet. 2024 Apr 29:S0140-6736(24)00532-4. doi: 10.1016/S0140-6736(24)00532.
    PubMed     Abstract available
    
    
    
47. ADEPOJU P
    Moderna stalls on African vaccine manufacturing plans.
    Lancet. 2024;403:1617.
    PubMed    
    
    
    
48. ASANTE KP, Mathanga DP, Milligan P, Akech S, et al
    Feasibility, safety, and impact of the RTS,S/AS01(E) malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi.
    Lancet. 2024 Apr 4:S0140-6736(24)00004-7. doi: 10.1016/S0140-6736(24)00004.
    PubMed     Abstract available
    
    
    
49. DAUBENBERGER CA, Silva JC
    First-generation malaria vaccine successfully implemented in three African countries.
    Lancet. 2024 Apr 4:S0140-6736(23)02892-1. doi: 10.1016/S0140-6736(23)02892.
    PubMed    
    
    
    March 2024
50. RAQIB R
    Bivalent conjugate vaccines for typhoid and paratyphoid fever.
    Lancet. 2024 Mar 28:S0140-6736(24)00461-6. doi: 10.1016/S0140-6736(24)00461.
    PubMed    
    
    
    
51. KULKARNI PS, Potey AV, Bharati S, Kunhihitlu A, et al
    The safety and immunogenicity of a bivalent conjugate vaccine against Salmonella enterica Typhi and Paratyphi A in healthy Indian adults: a phase 1, randomised, active-controlled, double-blind trial.
    Lancet. 2024 Mar 28:S0140-6736(24)00249-6. doi: 10.1016/S0140-6736(24)00249.
    PubMed     Abstract available
    
    
    
52. BURKI T
    Pivotal tuberculosis vaccine trial begins.
    Lancet. 2024;403:1125.
    PubMed    
    
    
    
53. SHAWE-TAYLOR M, Greenwood D, Hobbs A, Dowgier G, et al
    Divergent performance of vaccines in the UK autumn 2023 COVID-19 booster campaign.
    Lancet. 2024 Mar 11:S0140-6736(24)00316-7. doi: 10.1016/S0140-6736(24)00316.
    PubMed    
    
    
    
54. BURKI T
    The great cholera vaccine shortage.
    Lancet. 2024;403:891-892.
    PubMed    
    
    
    
55. PARHIZ H, Atochina-Vasserman EN, Weissman D
    mRNA-based therapeutics: looking beyond COVID-19 vaccines.
    Lancet. 2024 Mar 7:S0140-6736(23)02444-3. doi: 10.1016/S0140-6736(23)02444.
    PubMed     Abstract available
    
    
    February 2024
56. OCHOGE M, Futa AC, Umesi A, Affleck L, et al
    Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
    Lancet. 2024 Feb 22:S0140-6736(23)02844-1. doi: 10.1016/S0140-6736(23)02844.
    PubMed     Abstract available
    
    
    
57. COOPER LV, Blake IM
    First Africa-based clinical trial for novel type 2 oral poliovirus vaccine.
    Lancet. 2024 Feb 22:S0140-6736(24)00053-9. doi: 10.1016/S0140-6736(24)00053.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.